Amendment to Schedule 13D for Zenas Biopharma, Inc.

This Amendment No. 1 to the Schedule 13D for Zenas Biopharma, Inc. was filed by Longitude Venture Partners IV, L.P., Longitude Capital Partners IV, LLC, Longitude Prime Fund, L.P., Longitude Prime Partners, LLC, and individuals Patrick G. Enright and Juliet Tammenoms Bakker. The amendment reports changes in ownership following a private placement transaction (PIPE) where the company issued shares to institutional and accredited investors, including the reporting entities. On October 9, 2025, the reporting persons ceased to beneficially own more than 5% of the company's securities. The amendment also includes details of the Securities Purchase Agreement and Registration Rights Agreement related to the PIPE.